(Reuters) -Halozyme Therapeutics said on Wednesday it will buy privately held Elektrofi in a deal worth up to $900 million to expand its lineup with a technology that can deliver biologic medicines in small, concentrated doses.
The deal comprises of an upfront payment of $750 million and up to $150 million in milestone payments tied to three separate product approvals.
Elektrofi’s drug delivery technology known as Hypercon is designed to raise drug concentration to about 400–500 mg/ml, while keeping them easy to inject, making it possible for medicines to be given with small devices instead of larger infusions.
(Reporting by Padmanabhan Ananthan in Bengaluru)
Brought to you by www.srnnews.com
